Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jason Alan Carroll Insider Profile
4 Followers
Jason Alan Carroll, Director at Tryptamine Therapeutics, holds 36.75M shares in Tryptamine Therapeutics (Ticker: AU:TYP). Most recently, Jason Alan Carroll Bought AU$604,738 shares of Tryptamine Therapeutics on Jun 17, 2024 for an estimated value of 11.97K.
Jason Alan Carroll has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jason Alan Carroll's holdings
Insider Roles
Director
Roles that Jason Alan Carroll holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jason Alan Carroll
Jason Alan Carroll's Trading History
List of latest transactions for each holding click on a transaction to see Jason Alan Carroll's performance on stock
You May Also Like
Jason Alan Carroll insider profile FAQ
What is the percentage of profitable transactions made by Jason Alan Carroll?
The percentage of profitable transactions made by Jason Alan Carroll is ―.
What is the average return per transaction made by Jason Alan Carroll?
The average return per transaction made by Jason Alan Carroll is ―.
What stocks does Jason Alan Carroll hold?
Jason Alan Carroll holds: AU:TYP stocks.
What was Jason Alan Carroll’s latest transaction?
Jason Alan Carroll latest transaction was an Informative Buy of AU$11.97K.
What was Jason Alan Carroll's most profitable transaction?
Jason Alan Carroll’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jason Alan Carroll's role in Tryptamine Therapeutics?
Jason Alan Carroll's role in Tryptamine Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.